[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1997

Early Reactivation of Cytomegalovirus Retinitis Following Placement of a Ganciclovir Implant

Author Affiliations

Chicago, Ill

Arch Ophthalmol. 1997;115(6):802-803. doi:10.1001/archopht.1997.01100150804022

The ganciclovir implant (Vitrasert, Chiron, Emoryville, Calif) offers patients with cytomegalovirus (CMV) retinitis potential freedom from daily intravenous infusions or weekly intravitreal injections of ganciclovir, foscarnet, or both.1 Potential problems with this method of treatment include lack of systemic CMV coverage, no treatment of the contralateral eye, development of ganciclovir resistance, and direct complications of the implant surgery. We describe the reactivation of CMV retinitis that developed in a patient in the early postoperative period following ganciclovir implant placement. This potentially visionthreatening complication should be considered in any patient receiving the ganciclovir implant.

Report of a Case.  A 37-year-old man with human immunodeficiency virus was diagnosed with active granular CMV retinitis in the left eye. His visual acuity on presentation was 20/25 OD and 20/40 OS. The patient refused systemic treatment and a therapeutic regimen of weekly intravitreal injections of ganciclovir (200-2000 μg) was started. He responded dramatically to

First Page Preview View Large
First page PDF preview
First page PDF preview